BACKGROUND: Staphylococcus aureus infections remain a major complication of orthopaedic surgery. Although serum C-reactive protein is useful for diagnosis, there are no specific tests for host immunity that can assess a patient's risk for serious infection. On the basis of the identification of glucosaminidase as a potentially protective antigen in animal models, we tested the hypotheses that anti-glucosaminidase IgG (immunoglobulin G) levels vary in sera of mice and orthopaedic patients with Staphylococcus aureus infections and that physical and neutralizing titers correlate. METHODS: In vitro ELISAs (enzyme-linked immunosorbent assays) were developed to quantify binding (physical) and enzyme-neutralizing (functional) anti-glucosaminidase IgG titers. The assays were validated with use of sera from naive, Staphylococcus aureus-challenged, and glucosaminidase-immunized mice. The physical, functional, and isotype titers of anti-glucosaminidase IgG were measured in sera from twenty-four patients with a confirmed Staphylococcus aureus infection following orthopaedic surgery and in sera from twenty noninfected patients. The specificity of the anti-glucosaminidase assay was evaluated by means of linear regression and receiver-operator characteristic curve analysis. RESULTS: In mice, the analytic range of the physical titer assay for anti-glucosaminidase IgG was determined to be 1 ng/mL to 1 μg/mL, and physical titers correlated with functional titers (p < 0.002). Although all patients had measurable anti-glucosaminidase IgG, the physical titers in the infected patients were significantly higher by a factor of two compared with those in the healthy controls (p = 0.015). The physical titers were significantly correlated with the functional titers (p < 0.0001). Receiver-operator characteristic curve analysis demonstrated a diagnostic specificity of 0.72 (p = 0.014) for the assay. The anti-glucosaminidase titer in almost every patient was dominated by the IgG1 isotype. CONCLUSIONS: Humoral immunity against glucosaminidase varied in mammals with Staphylococcus aureus osteomyelitis. Anti-glucosaminidase titers in sera were a potential biomarker of infection and have the potential to assess the quality of host immunity against Staphylococcus aureus. CLINICAL RELEVANCE: Staphylococcus aureus infections can be challenging to diagnose, and there is no diagnostic test for host immunity. We demonstrated a cost-effective assay for determining the anti-glucosaminidase titer, which can be readily combined with conventional serology to improve diagnosis and to assess host immunity against Staphylococcus aureus.
BACKGROUND:Staphylococcus aureus infections remain a major complication of orthopaedic surgery. Although serum C-reactive protein is useful for diagnosis, there are no specific tests for host immunity that can assess a patient's risk for serious infection. On the basis of the identification of glucosaminidase as a potentially protective antigen in animal models, we tested the hypotheses that anti-glucosaminidase IgG (immunoglobulin G) levels vary in sera of mice and orthopaedic patients with Staphylococcus aureus infections and that physical and neutralizing titers correlate. METHODS: In vitro ELISAs (enzyme-linked immunosorbent assays) were developed to quantify binding (physical) and enzyme-neutralizing (functional) anti-glucosaminidase IgG titers. The assays were validated with use of sera from naive, Staphylococcus aureus-challenged, and glucosaminidase-immunized mice. The physical, functional, and isotype titers of anti-glucosaminidase IgG were measured in sera from twenty-four patients with a confirmed Staphylococcus aureus infection following orthopaedic surgery and in sera from twenty noninfected patients. The specificity of the anti-glucosaminidase assay was evaluated by means of linear regression and receiver-operator characteristic curve analysis. RESULTS: In mice, the analytic range of the physical titer assay for anti-glucosaminidase IgG was determined to be 1 ng/mL to 1 μg/mL, and physical titers correlated with functional titers (p &lt; 0.002). Although all patients had measurable anti-glucosaminidase IgG, the physical titers in the infectedpatients were significantly higher by a factor of two compared with those in the healthy controls (p = 0.015). The physical titers were significantly correlated with the functional titers (p &lt; 0.0001). Receiver-operator characteristic curve analysis demonstrated a diagnostic specificity of 0.72 (p = 0.014) for the assay. The anti-glucosaminidase titer in almost every patient was dominated by the IgG1 isotype. CONCLUSIONS: Humoral immunity against glucosaminidase varied in mammals with Staphylococcus aureus osteomyelitis. Anti-glucosaminidase titers in sera were a potential biomarker of infection and have the potential to assess the quality of host immunity against Staphylococcus aureus. CLINICAL RELEVANCE: Staphylococcus aureus infections can be challenging to diagnose, and there is no diagnostic test for host immunity. We demonstrated a cost-effective assay for determining the anti-glucosaminidase titer, which can be readily combined with conventional serology to improve diagnosis and to assess host immunity against Staphylococcus aureus.
Authors: Javad Parvizi; Ian M Pawasarat; Khalid A Azzam; Ashish Joshi; Erik N Hansen; Kevin J Bozic Journal: J Arthroplasty Date: 2010-05-31 Impact factor: 4.757
Authors: Linda Pasztor; Anne-Kathrin Ziebandt; Mulugeta Nega; Martin Schlag; Sabine Haase; Mirita Franz-Wachtel; Johannes Madlung; Alfred Nordheim; David E Heinrichs; Friedrich Götz Journal: J Biol Chem Date: 2010-09-16 Impact factor: 5.157
Authors: Simon R Clarke; Kirsten J Brummell; Malcolm J Horsburgh; Philip W McDowell; Sharifah A Syed Mohamad; Melanie R Stapleton; Jorge Acevedo; Robert C Read; Nicholas P J Day; Sharon J Peacock; James J Mond; John F Kokai-Kun; Simon J Foster Journal: J Infect Dis Date: 2006-03-13 Impact factor: 5.226
Authors: M Sugai; H Komatsuzawa; T Akiyama; Y M Hong; T Oshida; Y Miyake; T Yamaguchi; H Suginaka Journal: J Bacteriol Date: 1995-03 Impact factor: 3.490
Authors: C C Lee; R D Southgate; C Jiao; E Gersz; J R Owen; S L Kates; C A Beck; C Xie; J L Daiss; V Post; T F Moriarty; S Zeiter; E M Schwarz; G Muthukrishnan Journal: Eur Cell Mater Date: 2020-01-31 Impact factor: 3.942
Authors: Gowrishankar Muthukrishnan; Sandeep Soin; Christopher A Beck; Alex Grier; James D Brodell; Charles C Lee; Cheryl L Ackert-Bicknell; Frances Eun-Hyung Lee; Edward M Schwarz; John L Daiss Journal: Immunohorizons Date: 2020-06-22
Authors: Kohei Nishitani; Christopher A Beck; Alexander F Rosenberg; Stephen L Kates; Edward M Schwarz; John L Daiss Journal: Clin Orthop Relat Res Date: 2015-05-27 Impact factor: 4.176
Authors: Masahiro Ishikawa; Karen L de Mesy Bentley; Bryan J McEntire; B Sonny Bal; Edward M Schwarz; Chao Xie Journal: J Biomed Mater Res A Date: 2017-09-26 Impact factor: 4.396
Authors: Irvin Oh; Gowrishankar Muthukrishnan; Mark J Ninomiya; James D Brodell; Benjamin L Smith; Charles C Lee; Steven R Gill; Christopher A Beck; Edward M Schwarz; John L Daiss Journal: Infect Immun Date: 2018-11-20 Impact factor: 3.441
Authors: John J Varrone; Karen L de Mesy Bentley; Sheila N Bello-Irizarry; Kohei Nishitani; Sarah Mack; Joshua G Hunter; Stephen L Kates; John L Daiss; Edward M Schwarz Journal: J Orthop Res Date: 2014-07-03 Impact factor: 3.494
Authors: Gowrishankar Muthukrishnan; Christopher A Beck; John R Owen; Chao Xie; Stephen L Kates; John L Daiss Journal: J Orthop Res Date: 2020-12-25 Impact factor: 3.102
Authors: Stephen L Kates; John R Owen; Christopher A Beck; Chao Xie; Gowrishankar Muthukrishnan; John L Daiss; Edward M Schwarz Journal: J Bone Joint Surg Am Date: 2020-11-04 Impact factor: 6.558